Please login to the form below

situximab

This page shows the latest situximab news and features for those working in and with pharma, biotech and healthcare.

J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.

Boehringer/Lilly's empagliflozin among CHMP recommendations

There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior Account Director development role to Business Director, H...: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Add my company

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Redefining communications excellence: How to be heard in today’s multichannel, multistakeholder, multimedia world...
AstraZeneca: building a new ‘open innovation’ pharma company: The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
In conversation with Pfizer’s Erik Nordkamp: Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...